Registered number |
|
|
|
|
|
|||||||
Registered number: |
|
||||||
Balance Sheet | |||||||
as at |
|||||||
Notes | 2020 | 2019 | |||||
£ | £ | ||||||
Fixed assets | |||||||
Investments | 4 |
|
|
||||
Current assets | |||||||
Stocks |
|
|
|||||
Debtors | 5 |
|
|
||||
Cash at bank and in hand |
|
|
|||||
|
|
||||||
Creditors: amounts falling due within one year | 6 | ( |
( |
||||
Net current assets |
|
|
|||||
Net assets |
|
|
|||||
Capital and reserves | |||||||
Called up share capital |
|
|
|||||
Profit and loss account |
|
|
|||||
Shareholders' funds |
|
|
|||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
Mohamed Hanif Bhatia | |||||||
Director | |||||||
Approved by the board on |
|||||||
|
||||||||
Notes to the Accounts | ||||||||
for the year ended |
||||||||
1 | Accounting policies | |||||||
Basis of preparation | ||||||||
|
||||||||
Turnover | ||||||||
|
||||||||
Tangible fixed assets | ||||||||
|
||||||||
Plant and machinery | over 5 years | |||||||
Fixtures, fittings, tools and equipment | over 5 years | |||||||
Investments | ||||||||
|
||||||||
Stocks | ||||||||
|
||||||||
Debtors | ||||||||
|
||||||||
Creditors | ||||||||
|
||||||||
Taxation | ||||||||
|
||||||||
Provisions | ||||||||
|
||||||||
Foreign currency translation | ||||||||
|
||||||||
Pensions | ||||||||
|
||||||||
Basic financial instruments | ||||||||
A financial asset held as an equity instrument is recognised initially at the transaction price (including transaction costs). At the end of each reporting period, unlisted equity investments are recorded at fair value, where appropriate, or at cost less impairmentif their value cannot be reliably measured. Objective evidence of the impairment of financial assets is assessed at each period end and any impairment loss recognised in the profit or loss immediately. Impairment loss is calculated as the difference between the carrying amount of the instrument and the best estimate of the cash flows expected to be derived from the asset(including sales proceeds if sold) at the balance sheet date. Investment income is recognised in the financial statements when the company becomes entitled to its share of profits from the financial instruments. |
||||||||
2 | Employees | 2020 | 2019 | |||||
Number | Number | |||||||
Average number of persons employed by the company |
|
|
||||||
3 | Tangible fixed assets | |||||||
Plant and machinery etc | ||||||||
£ | ||||||||
Cost | ||||||||
At 1 March 2019 |
|
|||||||
At 29 February 2020 |
|
|||||||
Depreciation | ||||||||
At 1 March 2019 |
|
|||||||
At 29 February 2020 |
|
|||||||
Net book value | ||||||||
At 29 February 2020 | - | |||||||
4 | Investments | |||||||
Other | ||||||||
investments | ||||||||
£ | ||||||||
Cost | ||||||||
At 1 March 2019 |
|
|||||||
At 29 February 2020 |
|
|||||||
5 | Debtors | 2020 | 2019 | |||||
£ | £ | |||||||
Trade debtors |
|
|
||||||
Other debtors |
|
|
||||||
|
|
|||||||
6 | Creditors: amounts falling due within one year | 2020 | 2019 | |||||
£ | £ | |||||||
Other loans | 14,490 | 14,990 | ||||||
Trade creditors |
|
|
||||||
Taxation and social security costs |
|
|
||||||
Other creditors |
|
|
||||||
Director's account | 17,959 | 481 | ||||||
Accruals | 18,040 | 4,445 | ||||||
|
|
|||||||
7 | Provision for liabilities | |||||||
The company is a member of I. F. R&D LLP and is liable to contribute to the assets of the LLP in the event of a winding up before 1 July 2020. The maximum liability in relation to this undertaking is £149,742. The company does not believe that a winding up of the LLP is probable and has not made provision for the liability at 28 February 2020. The company is also member of Cerenet LLP and is liable to contribute to the assets of the LLP in the event of a winding up before 1 March 2021. The maximum liability in ralation to this undertaking is £152,160. The company does not believe that a winding up of the LLP is probable and has not made provision for the liability at 28 February 2020. The company is a member of Leupraza LLP and is liable to contribute to the assets of the LLP in the event of a winding-up before 1 February 2022. The maximum liability in relation to this undertaking is £126,469. The company does not believe that a winding-up of the LLP is probable and has not made provision for the liability at 28 February 2020. |
||||||||
8 | Related party transactions | |||||||
|
||||||||
9 | Controlling party | |||||||
|
||||||||
10 | Other information | |||||||
Zerenex Molecular Limited is a private company limited by shares and incorporated in England. Its registered office is: | ||||||||
32 Westland Avenue | ||||||||
Bolton | ||||||||
Lancashire | ||||||||
BL1 5NP |